Linkage between patients' characteristics and prescribed systemic treatments for Psoriasis: a semantic connectivity map analysis of the Swiss SDNTT registry

Cazzaniga, S. and Anzengruber, F. and Augustin, M. and Boehncke, W. H. and Borradori, L. and Conrad, C. and Cozzio, A. and Djamei, V. and French, L. E. and Gilliet, M. and Häusermann, P. and Heidemeyer, K. and Itin, P. and Kolios, A. G. A. and Laffitte, E. and Maul, J.-T. and Mainetti, C. and Naldi, L. and Navarini, A. A. and Rustenbach, S. J. and Simon, D. and Sorbe, C. and Streit, M. and Yawalkar, N.. (2019) Linkage between patients' characteristics and prescribed systemic treatments for Psoriasis: a semantic connectivity map analysis of the Swiss SDNTT registry. Journal of the European Academy of Dermatology and Venereology : JEADV, 33 (12). pp. 2313-2318.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/72181/

Downloads: Statistics Overview


Several treatment options are currently available for the treatment of psoriasis.; To explore the main associations between patients' characteristics and systemic treatments prescribed for psoriasis in a large group of patients observed in real life clinical practice.; This was a retrospective analysis of baseline data collected within the Swiss Dermatology Network for Targeted Therapies registry in Switzerland between March 2011 and December 2017. Semantic map analysis was used in order to capture the best associations between variables taking into account other covariates in the system.; 549 patients (mean age 46.7±14.7 years) were included in the analysis. Conventional therapies like retinoids and methotrexate were associated with no previous systemic therapies for psoriasis, a moderate quality of life (QoL) at therapy onset and older age (≥60 years). Fumaric acid derivatives were associated with mild psoriasis (PASI<10) and long disease duration (≥20 years). On the other side, cyclosporine and PUVA/UVB treatments were linked to a more severe condition, including impaired QoL, hospitalisation and inability to work. Regarding biological therapies, both infliximab and adalimumab were connected to the presence of psoriatic arthritis, severe disease condition and other comorbidities, including chronic liver or kidney diseases and tuberculosis. Etanercept, ustekinumab and secukinumab were all connected to a complex history of previous systemic treatments for psoriasis, moderate disease condition, overweight and university education.; The analysis shows multifaceted associations between patients' characteristics, comorbidities, disease severity and systemic treatments prescribed for psoriasis. In particular, our semantic map indicates that comorbidities play a central role in decision-making of systemic treatments usage for psoriasis. Future studies should further investigate specific connections emerging from our data.
Faculties and Departments:03 Faculty of Medicine > Bereich Spezialfächer (Klinik) > Dermatologie USB > Dermatologie (Navarini)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Spezialfächer (Klinik) > Dermatologie USB > Dermatologie (Navarini)
UniBasel Contributors:Navarini, Alexander
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:09 Jul 2020 15:28
Deposited On:09 Jul 2020 15:28

Repository Staff Only: item control page